Delivery Order SPE2DB25D3012-SPE2DB25FWZTP
- Not listed
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $1,054.35. This is a firm fixed price, non-set-aside delivery order executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026. The performance...
- The Defense Logistics Agency awarded a $12,030.04 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of NovoLog 100 Unit/ML FlexPen 3ML insulin pens. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 4, 2025. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $2,108.70. This competitively awarded, non-set-aside contract represents a firm fixed price delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a $3,903.98 firm fixed price delivery order to AmerisourceBergen Drug Corp on June 5, 2025, for NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The product will be delivered to the company's headquarters in Conshohocken, Pennsylvania, with an ultimate completion date of June 6, 2025. This delivery...
- The Defense Logistics Agency awarded a $5,863.86 delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of August 21, 2025. The product will be delivered to the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order valued at $1,405.80 to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded transaction. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of August 26, 2025. This order falls under...
- The Defense Logistics Agency awarded a $3,064.44 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The contract, which represents a non-competitive delivery order, will be performed at the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of September 10, 2025. This award falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $4,966.59. This is a firm fixed-price delivery order with no set-aside designation, performed at the contractor's corporate office location in Conshohocken, Pennsylvania, and scheduled for completion by September 18, 2025. The order is issued under AmerisourceBergen's Indefinite Delivery...
- The Defense Logistics Agency awarded a $3,016.18 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The contract is a non-set-aside competitive award with an ultimate completion date of September 12, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,537.84 firm fixed price delivery order on July 29, 2025, for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of July 30, 2025. This non-competitive delivery order was placed against AmerisourceBergen's existing indefinite delivery contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and running through December 2026. The product will be delivered to the...
- SPE2DB25D3012Indefinite Delivery Contract
- SPE2DB25D3012-SPE2DB25FWZTPDelivery Order
The Defense Logistics Agency awarded a $3,795.66 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of NovoLog 100 Unit/ML FlexPen 3ML insulin pens. This is a firm fixed price delivery order under a competitive, non-set-aside procurement. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of September 4, 2025. This delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical supply vehicle running through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement across the Defense Health System. The SPE2DX prime contract enables the company to supply a broad range of pharmaceutical products and medical commodities to support military healthcare programs globally, including specialty medications, vaccines, and medical supplies across multiple therapeutic domains. This specific delivery order for diabetes medication reflects the company's ongoing role in supporting military medical supply chain requirements through the DLA's pharmaceutical procurement operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.8k | 9/3/25 |